Learning from the best! Our first Speed Mentoring event was a success, thanks to our Executive Leadership Team sharing their valuable insights on career development. Take a peek at some of the key takeaways from the day. #mentoringmatters #OneIntellia
Intellia Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 55,382 followers
Developing curative genome editing treatments
About us
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
- Website
-
http://www.intelliatx.com
External link for Intellia Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
40 Erie Street
Cambridge, Massachusetts 02139, US
Employees at Intellia Therapeutics, Inc.
Updates
-
We are proud to share Intellia has earned a place on the Seramount 2024 100 Best Companies list for its commitment to #diversityandinclusion and being a family-friendly workplace. Congratulations to all who were recognized! #OneIntellia $NTLA #Seramount100Best https://lnkd.in/eNFte8kh
🎉 Congratulations to #Seramount's 2024 100 Best Companies! 🎉 Our rigorous selection process involved over 200 questions related to leave policies, benefits, childcare, advancement programs, and flexibility. These companies have demonstrated exceptional commitment to creating supportive and inclusive workplaces. We’d like to extend a special congratulations to this year’s #1 company, Johnson & Johnson. To the winners, thank you for setting the standard and leading the way in workplace excellence! 🌟 Learn more about all the winners and methodology here: https://bit.ly/4cCajDh #BestCompanies #WorkplaceExcellence #DiversityAndInclusion #EmployeeEngagement #Seramount
-
-
Intellia Therapeutics, Inc. reposted this
#CRS2024 Reflecting on an impressive plenary lecture by Dr. Laura Sepp-Lorenzino, Ph.D. from Intellia Therapeutics, Inc., titled "Realizing the Promise of In Vivo CRISPR Therapeutics." Well in fact, it's more than a promise. Thanks to #Nanomedicine, we are now at the beginning of a true medical revolution. Dr. Sepp-Lorenzino delved into Intellia's pioneering work with CRISPR/Cas9 technologies delivered by systemic lipid nanoparticles (LNPs). Notably, onoing clinical trials have shown impressive improvements in patients with hereditary transthyretin amyloidosis (ATTR) and for hereditary angioedema (HAE), aiming to provide continuous reduction of symptoms with a single dose. HAE is a rare, autosomal dominant disorder characterized by recurrent episodes of severe swelling, which can be potentially fatal if not identified early and drastically impact the quality of life of patients. Current treatments are effective but expensive, and there is no cure yet. During the very active Q&A, Dr. Sepp-Lorenzino emphasized the key role of nanomedicine but also highlighted the variability in LNP quality (that we see in virtually all research papers nowadays): "I'm happy with my LNP... But...not all LNP are the same." she said. Couldn't agree more. At the European Technology Platform for Nanomedicine (ETPN Association), we are addressing these challenges, notably through two great European collaborative projects: METRINO Project: Producing SOPs and reference materials to help academia and industry better qualify and standardize nanomedicine, notably including LNPs indeed. NANOSPRESSO-NL: Revolutionizing the paradigm of Nanomedicine for rare diseases through bedside production of small batches of high-quality RNA-LNP, to bypass the many constraints of scale-up. We develop this concept for rare and orphan diseases like Methylmalonic acidemia (MMA), a metabolic genetic condition leading to the accumulation of substances in cells that cause damage to the brain, liver, kidneys, and other organs. We even integrate regulatory science research in the process to understand how this new concept could fit current and future regulations. I highly recommend all friends and colleagues of the Nanomedicine community to follow these two projects of interest, at least on LinkedIn. Get involved! :) This lecture truly underscored the transformative potential of CRISPR technology in modern medicine. What a fantastic period: finally, we can see treatments coming for those millions of patients who struggle with rare and orphan diseases. #CRS2024 #CRISPR #GeneTherapy #Nanomedicine #Innovation #Healthcare cc Raymond Schiffelers Olivia Lewis Marieke De Bruin Andreas Åslund Sven Even F. Borgos Solstice Pharmaceuticals B.V. UMC Utrecht Robin Schürmann Enrica Alasonati Leonardo Mortati Marco Monopoli Lorena Diéguez meriem lamghari Neill Liptrott Marco Monopoli Giovanni Tosi Steven Conlan Kathleen Spring et al.
-
-
We’re 10!🧬Join us as we look back on our biggest breakthroughs and provide an inside look into some of the great minds and passion that drive us. Hear from CEO John Leonard, M.D., on how it all started. #IntelliaTurns10 #GenomeJourney $NTLA www.intelliatx.com
-
Our Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D., will speak on “Realizing the Promise of In Vivo CRISPR Therapeutics” at the Controlled Release Society 2024 Annual Meeting and Exposition in Bologna, Italy, on July 12. Details here: https://lnkd.in/gNgW-eZm #geneediting #CRISPR
-
Intellia announces new data from patients redosed with an investigational in vivo #CRISPR-based therapy at the Peripheral Nerve Society Annual Meeting. Full details here: https://lnkd.in/eGxiDYCm #geneeediting #PNS2024
-
Tomorrow at the International Society on Thrombosis and Haemostasis (ISTH) Congress, Dr. Remy Petersen from Amsterdam University Medical Center will present a poster on Intellia’s investigational #HAE program, titled “Reduction of plasma kallikrein by in vivo CRISPR-based gene editing of KLKB1 does not alter coagulation in patients with #hereditaryangioedema.” Learn more: https://www.isth2024.org/ #ISTH2024
-
Meet Ramsey, a director in Delivery Sciences, Delivery Physics and Biology. He is inspired by his colleagues and the insights they have provided him during his past six years at Intellia. Stay tuned for more employee career journeys this summer! #OneIntellia #IntelliaCareerJourneys
-
Today, we celebrate African-American resilience and the power of progress in honor of #Juneteenth. As we recognize the significance of this historic day, let's continue to strive towards a more equitable future for all.
-
Intellia Vice President, Disease Biology, Sean Burns M.D., will be presenting about Intellia’s #CRISPR #geneediting platform at this week’s Federation of American Societies for Experimental Biology (FASEB) Genome Engineering Conference in Rome, Italy, on June 20. https://lnkd.in/ePhvDw_j #GENESRC